BioSpace News Archive

Biosenta Inc. (“Biosenta” or the “Company”) (CSE: ZRO) is thrilled to announce a pivotal discovery led by Dr. Mehdi Mohammadi Ashani, a Postdoctoral Researcher under the mentorship of Dr. Ian Lewis and Dr. Maen Husein at the University of Calgary.

Orsini Specialty Pharmacy has been selected by Amicus Therapeutics to dispense Pombiliti™ and Opfolda™, a two-component treatment approved for certain patients with late-onset Pompe disease.

Nanostics is thrilled to announce the availability of the ClarityDX Prostate test at its newly accredited clinical lab in Edmonton, Alberta.

The closing of the offering is expected to occur on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

TransCode Therapeutics, Inc. announced the closing of its previously announced public offering of an aggregate of 16,863,000 shares of its common stock in lieu thereof), including the partial exercise of the underwriter’s over-allotment option.

ModeX Therapeutics Inc., an OPKO Health, Inc. company, has been awarded a contract from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases.

ApollomicsInc. (Nasdaq: APLM) (the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced its financial results for the six months ended June 30, 2023, and provided a corporate update.

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced that the Company has entered into a partnership with ResMed Germany to increase OSA awareness and therapy penetration in the German market.

Medicenna Therapeutics Corp. announced the voting results from the Company’s annual and special meeting of shareholders held September 28, 2023.

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced that Chief Executive Officer Masoud Toloue will speak on a panel at Goldman Sachs Alzheimer’s Disease Day on Tuesday, October 3, 2023.